23 April 2018

Vectura Group appoints Anne Whitaker to its Board of Directors

 

Chippenham, UK – 23 April 2018: Vectura Group plc (LSE: VEC) (“Vectura”, the “Group”, or the “Company”), an industry-leading inhaled product formulation, device design and development business, is pleased to announce the appointment of Anne Whitaker as an Independent Non-Executive Director of the Company with effect from 1 June 2018.

Anne has more than 25 years of experience in the life science industry, including senior leadership roles with large pharmaceutical, biotech, and speciality pharma companies. She has significant experience in the US respiratory sector and was, until recently, serving as President and Chief Executive Officer of KNOW Bio, LLC and its wholly owned subsidiary, Novoclem Therapeutics, Inc., a company focused on helping patients who suffer from severe respiratory diseases.  Previously, Anne was Executive Vice President and Company Group Chairman at Valeant Pharmaceuticals, where she was responsible for overseeing its Branded Pharmaceutical Business.  Prior to that, Anne served as President and Chief Executive Officer of Synta Pharmaceuticals, now part of Madrigal Pharmaceuticals, Inc.  She also served as President, North America Pharmaceuticals at Sanofi, where she oversaw all pharmaceutical and consumer healthcare operations for the region, and held several commercial leadership roles at GlaxoSmithKline. 

Anne is currently an Independent Director of Cree, Inc., a NASDAQ traded company and has been nominated to serve as an independent director of Mallinckrodt plc pending their shareholder vote at the Annual General Meeting in May, 2018.

 

“I am delighted to welcome Anne to the Vectura Board. As part of our Board succession and planning work we have, for some time, been seeking to identify an appropriate Non-Executive Director with current US pharma experience to replace Frank Condella, who has provided such excellent service to the Skyepharma and, subsequently, Vectura Boards for over 12 years. Anne fits this brief extremely well. Anne’s knowledge and experience will, I am sure, be extremely valuable as the Company moves forward with its stated strategy to be an industry-leading inhaled drug-device specialist. It is intended that, once Anne’s appointment becomes effective on 1st June 2018, and following a reasonable hand over period, Frank Condella will step down from the Board. A further announcement will be made at that time."

Bruno Angelici

Chairman of Vectura

“I am extremely excited to be joining the Board of Vectura during this important time for the Company. I look forward to working closely with the Board and senior management to help Vectura fully leverage its differentiated technology and unique integrated capabilities to maximise value for shareholders and, ultimately, for patients.”

Anne Whitaker

There are no additional details to disclose under Listing Rule 9.6.13 (1) to (6) in respect of the appointment of Anne Whitaker.

 

Ends

 

Enquiries

Vectura Group plc

+44 (0)1249 667 700

 

David Ginivan – Vice President Communications

Julia Wilson – Director Investor Relations

 

 

Consilium Strategic Communications

+44 (0)20 3709 5700

Mary-Jane Elliott / Philippa Gardner / Jessica Hodgson

 vectura@consilium-comms.com

 

About Vectura

Vectura is an industry-leading inhaled product formulation, device design and development business offering a uniquely integrated inhaled drug delivery platform. We develop inhalation products to help patients suffering from airways diseases.

Vectura has eight key inhaled, two non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a diverse partnered portfolio of drugs in clinical development.  Our partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Bayer, Chiesi, Almirall, Janssen, Dynavax and Tianjin KingYork.

Vectura’s strategy is to fully leverage its differentiated technology and skills, maximising value by enhancing the delivery and performance of inhaled products and through the development of high-quality generic alternatives to branded therapies. 


Back to previous page